Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of GBP 11.15 billion. The enterprise value is 8.92 billion.

Market Cap	11.15B
Enterprise Value	8.92B

Important Dates

The last earnings date was Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-1.94%
Shares Change (QoQ)	+0.39%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	62.85M

Valuation Ratios

The trailing PE ratio is 12.82.

PE Ratio	12.82
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.75, with an EV/FCF ratio of 10.61.

EV / Earnings	10.26
EV / Sales	3.74
EV / EBITDA	10.75
EV / EBIT	11.37
EV / FCF	10.61

Financial Position

The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.

Current Ratio	5.25
Quick Ratio	5.24
Debt / Equity	0.03
Debt / EBITDA	0.14
Debt / FCF	0.14
Interest Coverage	58.99

Financial Efficiency

Return on equity (ROE) is 22.97% and return on invested capital (ROIC) is 12.62%.

Return on Equity (ROE)	22.97%
Return on Assets (ROA)	10.91%
Return on Invested Capital (ROIC)	12.62%
Return on Capital Employed (ROCE)	17.48%
Revenue Per Employee	889,990
Profits Per Employee	324,309
Employee Count	2,682
Asset Turnover	0.53
Inventory Turnover	16.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.83% in the last 52 weeks. The beta is 0.86, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-20.83%
50-Day Moving Average	1,488.64
200-Day Moving Average	1,685.11
Relative Strength Index (RSI)	67.49
Average Volume (20 Days)	24,885

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of GBP 2.39 billion and earned 869.80 million in profits. Earnings per share was 13.46.

Revenue	2.39B
Gross Profit	2.28B
Operating Income	784.97M
Pretax Income	1.02B
Net Income	869.80M
EBITDA	819.45M
EBIT	784.97M
Earnings Per Share (EPS)	13.46

Full Income Statement

Balance Sheet

The company has 2.34 billion in cash and 114.10 million in debt, giving a net cash position of 2.23 billion.

Cash & Cash Equivalents	2.34B
Total Debt	114.10M
Net Cash	2.23B
Net Cash Per Share	n/a
Equity (Book Value)	4.07B
Book Value Per Share	64.04
Working Capital	2.50B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 861.70 million and capital expenditures -20.74 million, giving a free cash flow of 840.97 million.

Operating Cash Flow	861.70M
Capital Expenditures	-20.74M
Free Cash Flow	840.97M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 95.42%, with operating and profit margins of 32.89% and 36.44%.

Gross Margin	95.42%
Operating Margin	32.89%
Pretax Margin	42.57%
Profit Margin	36.44%
EBITDA Margin	34.33%
EBIT Margin	32.89%
FCF Margin	35.23%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.94%
Shareholder Yield	1.94%
Earnings Yield	7.80%
FCF Yield	7.54%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 10.02.

Altman Z-Score	10.02
Piotroski F-Score	n/a